CBE
MCID: CHR682
MIFTS: 38

Chronic Bilirubin Encephalopathy (CBE)

Categories: Metabolic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Chronic Bilirubin Encephalopathy

MalaCards integrated aliases for Chronic Bilirubin Encephalopathy:

Name: Chronic Bilirubin Encephalopathy 58
Bilirubin-Induced Neurological Dysfunction 58
Kernicterus Spectrum Disorder 58
Bind 58
Cbe 58
Ksd 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Inborn errors of metabolism


Summaries for Chronic Bilirubin Encephalopathy

MalaCards based summary : Chronic Bilirubin Encephalopathy, also known as bilirubin-induced neurological dysfunction, is related to corticosteroid-binding globulin deficiency and mannose-binding lectin deficiency. The drugs Apomorphine and Vancomycin have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and lung, and related phenotypes are neonatal hyperbilirubinemia and prolonged neonatal jaundice

Wikipedia : 74 Kernicterus is a bilirubin-induced brain dysfunction. The term was coined in 1904 by Schmorl. Bilirubin... more...

Related Diseases for Chronic Bilirubin Encephalopathy

Diseases in the Acute Bilirubin Encephalopathy family:

Chronic Bilirubin Encephalopathy

Diseases related to Chronic Bilirubin Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3842)
# Related Disease Score Top Affiliating Genes
1 corticosteroid-binding globulin deficiency 12.7
2 mannose-binding lectin deficiency 12.7
3 inherited thyroxine-binding globulin deficiency 12.6
4 core binding factor acute myeloid leukemia 12.6
5 mannose-binding lectin protein deficiency 12.5
6 thyroxine-binding globulin quantitative trait locus 12.4
7 sex hormone-binding globulin circulating level quantitative trait locus 12.4
8 hemolytic poikilocytic anemia due to reduced ankyrin binding sites 12.3
9 urate-binding globulin, decrease in 12.3
10 congenital hypothyroidism due to transplacental passage of tsh-binding inhibitory antibodies 12.1
11 lung cancer 11.7
12 tangier disease 11.6
13 scott syndrome 11.6
14 hyperlipoproteinemia, type id 11.6
15 rheumatoid arthritis 11.6
16 antithrombin iii deficiency 11.6
17 pseudo-von willebrand disease 11.6
18 satb2-associated syndrome 11.6
19 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 11.5
20 zinc, elevated plasma 11.5
21 surfactant metabolism dysfunction, pulmonary, 3 11.5
22 neuromyelitis optica 11.4
23 von willebrand disease, type 2 11.4
24 cyanosis, transient neonatal 11.4
25 masp2 deficiency 11.4
26 hemoglobin zurich 11.4
27 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 11.4
28 biotin deficiency 11.4
29 cold agglutinin disease 11.4
30 holocarboxylase synthetase deficiency 11.4
31 retinoblastoma 11.4
32 neuroblastoma 11.4
33 tetanus 11.3
34 huntington disease 11.3
35 rickets 11.3
36 cervical cancer 11.3
37 wiskott-aldrich syndrome 11.3
38 connective tissue disease 11.3
39 asthma 11.3
40 oculopharyngeal muscular dystrophy 11.3
41 adrenoleukodystrophy 11.3
42 spinocerebellar ataxia 17 11.3
43 pemphigus vulgaris, familial 11.3
44 acid-labile subunit deficiency 11.3
45 attention deficit-hyperactivity disorder 11.3
46 cardiomyopathy, familial hypertrophic, 4 11.3
47 pseudoxanthoma elasticum 11.3
48 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 11.3
49 niemann-pick disease, type c1 11.3
50 mecp2 disorders 11.3

Graphical network of the top 20 diseases related to Chronic Bilirubin Encephalopathy:



Diseases related to Chronic Bilirubin Encephalopathy

Symptoms & Phenotypes for Chronic Bilirubin Encephalopathy

Human phenotypes related to Chronic Bilirubin Encephalopathy:

58 31 (show all 21)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neonatal hyperbilirubinemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003265
2 prolonged neonatal jaundice 58 31 hallmark (90%) Very frequent (99-80%) HP:0006579
3 hepatic encephalopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0002480
4 abnormal auditory evoked potentials 58 31 hallmark (90%) Very frequent (99-80%) HP:0006958
5 intellectual disability 58 31 frequent (33%) Frequent (79-30%) HP:0001249
6 seizures 58 31 frequent (33%) Frequent (79-30%) HP:0001250
7 feeding difficulties 58 31 frequent (33%) Frequent (79-30%) HP:0011968
8 sensorineural hearing impairment 58 31 frequent (33%) Frequent (79-30%) HP:0000407
9 hypertonia 58 31 frequent (33%) Frequent (79-30%) HP:0001276
10 central apnea 58 31 frequent (33%) Frequent (79-30%) HP:0002871
11 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
12 hemolytic anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001878
13 cerebral palsy 58 31 frequent (33%) Frequent (79-30%) HP:0100021
14 hypoalbuminemia 58 31 frequent (33%) Frequent (79-30%) HP:0003073
15 abnormal thalamic mri signal intensity 58 31 frequent (33%) Frequent (79-30%) HP:0012696
16 kernicterus 58 31 frequent (33%) Frequent (79-30%) HP:0001343
17 conjunctival icterus 58 31 frequent (33%) Frequent (79-30%) HP:0032106
18 neonatal sepsis 58 31 occasional (7.5%) Occasional (29-5%) HP:0040187
19 hypernatremia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003228
20 visual gaze preference 58 31 occasional (7.5%) Occasional (29-5%) HP:0025518
21 abnormal conjunctiva morphology 58 Frequent (79-30%)

Drugs & Therapeutics for Chronic Bilirubin Encephalopathy

Drugs for Chronic Bilirubin Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 751)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Apomorphine Approved, Investigational Phase 4 58-00-4, 41372-20-7 6005
2
Vancomycin Approved Phase 4 1404-90-6 441141 14969
3
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
4
Eplerenone Approved Phase 4 107724-20-9 150310 443872
5
Tirofiban Approved Phase 4 144494-65-5 60947
6
tannic acid Approved Phase 4 1401-55-4
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
Bevacizumab Approved, Investigational Phase 4 216974-75-3
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
11
Gliclazide Approved Phase 4 21187-98-4 3475
12
Glyburide Approved Phase 4 10238-21-8 3488
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Mivacurium Approved Phase 4 133814-19-4, 106791-40-6 5281042
15
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
16
Zolpidem Approved Phase 4 82626-48-0 5732
17
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
18
Ezetimibe Approved Phase 4 163222-33-1 150311
19
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
20
Enoxaparin Approved Phase 4 9005-49-6 772
21
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
22
Ranibizumab Approved Phase 4 347396-82-1 459903
23
Povidone-iodine Approved Phase 4 25655-41-8
24
Ferrous succinate Approved Phase 4 10030-90-7
25 Tomato Approved Phase 4
26
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
27
Petrolatum Approved, Investigational Phase 4 8009-03-8
28
Citalopram Approved Phase 4 59729-33-8 2771
29
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
30
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
31 Poractant alfa Approved Phase 4 129069-19-8
32
Budesonide Approved Phase 4 51333-22-3 63006 5281004
33
Mycophenolic acid Approved Phase 4 24280-93-1 446541
34
Dimenhydrinate Approved Phase 4 523-87-5 441281
35
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
36
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
37
Abatacept Approved Phase 4 332348-12-6 10237
38
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
39
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
40
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
41
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
42 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
43
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
44
Sertraline Approved Phase 4 79617-96-2 68617
45
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
46
Colestipol Approved Phase 4 26658-42-4
47
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
48
Promethazine Approved, Investigational Phase 4 60-87-7 4927
49
Suvorexant Approved, Investigational Phase 4 1030377-33-3
50
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816

Interventional clinical trials:

(show top 50) (show all 737)
# Name Status NCT ID Phase Drugs
1 Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs Unknown status NCT03082573 Phase 4 H.P. Acthar gel
2 Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease Unknown status NCT02940912 Phase 4 Apomorphine;Placebo
3 Study on the Effect of Combined Oral Contraceptive Therapy on Female Sexuality, Body Image and Mental Health Unknown status NCT02613039 Phase 4 Combined Estrogen-Progestin Oral Contraceptives
4 Randomized Comparison of Zotarolimus- and Everolimus-Eluting Stents for Coronary Treatment Unknown status NCT00768846 Phase 4
5 Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia: A Pilot Study Unknown status NCT02478710 Phase 4 Aerosolized Tobramycin or Vancomycin;Aerosolized Placebo
6 Supplementation With Lactoferrin in Preterm Newborns Unknown status NCT01172236 Phase 4 Lactoferrin;Lactoferrin
7 Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? Unknown status NCT00553722 Phase 4 Eplerenone;Placebo
8 A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention Unknown status NCT00407771 Phase 4 Tirofiban
9 Acetaminophen Adduct Formation in Alcohol Abstaining Subjects Administered Therapeutic Doses of Acetaminophen for Ten Consecutive Days Completed NCT00616018 Phase 4 acetaminophen
10 Prospective, Pivotal Unicentre, Randomized Double-bind, Placebo-controlled Study, to Evaluate Efficacy and Safety of Bacterial Lysates (Pulmonarom) in the Prevention of Respiratory Tract Infections Completed NCT00599417 Phase 4 Bacterial Lysates;placebo
11 The Early Reversibility of Rocuronium After Different Doses of Neostigmine Completed NCT00001520 Phase 4 neostigmine
12 Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. Completed NCT03384511 Phase 4 Apatinib
13 Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study Completed NCT02201602 Phase 4 Gliclazide;Glibenclamide
14 International Multicenter Double-bind Placebo-controlled Randomized Parallel-group Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity Completed NCT03301155 Phase 4 Anaferon for children;Placebo
15 Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.5) Completed NCT00895609 Phase 4 Sugammadex, Neostigmine, Saline
16 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
17 Effect of Deep BLock on Intraoperative Surgical Conditions, Perioperative Hemodynamic Status and Respiratory Parameters Following Reversal With Sugammadex in Patients Undergoing Laparoscopic Renal and Prostate Surgery. Completed NCT01631149 Phase 4 Surgical block (rocuronium; atracurium/mivacurium);Surgical block (rocuronium; atracurium/mivacurium)
18 The Use of MI Varnish for the Prevention and Reduction of White Spot Lesions in Orthodontic Treatment Completed NCT03446690 Phase 4 MI Varnish
19 A Study of the Safety of Ramelteon in Elderly Subjects Completed NCT00568789 Phase 4 Ramelteon, zolpidem and placebo
20 Impact of Phytoestrogens on Serum Lipids in Postmenopausal Women Completed NCT01497977 Phase 4 phytoestrogens;phytoestrogens
21 Prophylactic Recombinant Tissue Plasminogen Activator in the Prevention of Central Venous Access Device (CVAD)-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome Completed NCT02355743 Phase 4 rtPA lock therapy
22 Evaluation of Endothelial Progenitor Cell (EPC) Capturing (GENOUS) Stent After Coronary Stenting Utilizing Optical Coherence Tomography (OCT): the EGO Study Completed NCT01272895 Phase 4
23 Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons in Men With Stable Coronary Heart Disease. Completed NCT00481351 Phase 4 Simvastatin 20mg plus ezetimibe 10mg;ezetimibe;simvastatin 20mg;Simvastatin 80mg
24 Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up Completed NCT01863134 Phase 4 Eptifibatide;Placebo
25 Comparison of Bivalirudin and Unfractioned Heparin in Elective Percutaneous Coronary Interventions Completed NCT00448461 Phase 4 heparin;bivalirudin
26 Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements? Completed NCT03219294 Phase 4 Vecuronium 0.1 mg/kg;Vecuronium 0.2mg/kg
27 Effects of Low Doses of Ketamine on Postoperative Quality of Recovery After Total Intravenous Anesthesia Completed NCT02571153 Phase 4 Ketamine 0.4 mg/kg;Normal saline;Ketamine 0.2 mg/kg
28 A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
29 The Efficacy and Safety of Vitamin C for Iron Supplementation Therapy in Adult Patients With Iron Deficiency Anemia(IDA) Completed NCT02631668 Phase 4 ferrous succinate and vitamin C;ferrous succinate;ferrous succinate
30 Minimally Invasive Treatment for Papillae Deficiencies in Esthetic Zone Using Hyaluronic Acid Completed NCT02876276 Phase 4
31 Effect of Replacement Volume and AST-120 (Kremezin) on Protein-bound Toxins, Oxidative Stress and MicroInflammation in Patients Receiving Online Hemodiafiltration Completed NCT01458652 Phase 4 Kremezin
32 Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects at High Estimated Cardiovascular Risk Completed NCT03206944 Phase 4 acetylsalicylic acid;Tomato Fruit Extract
33 The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis Completed NCT00179959 Phase 4 Sodium hypochlorite (bleach) baths;Mupirocin ointment;Water;Petrolatum Ointment
34 Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression Completed NCT03207438 Phase 4 Quetiapine 50 MG Extended Release Oral Tablet;Quetiapine Fumarate XR 150-300 mg;Placebos
35 A Phase IV OpenLabelled Prospective Pilot Study of Intravitreal Macugen (Pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME Study) Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
36 Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-based Neurointerventional Procedures Recruiting NCT03322657 Phase 4 Neostigmine;Glycopyrrolate;Sugammadex
37 Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. Recruiting NCT03521063 Phase 4 Budesonide;Poractant Alfa;Saline
38 Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography Recruiting NCT01683825 Phase 4 F-18 florbetapir PET
39 A Placebo-controlled Trial With Citalopram for the Treatment of Typical Reflux Symptoms in Patients With Reflux Hypersensitivity or Functional Heartburn With Incomplete Proton Pump Inhibitor Response Recruiting NCT03499171 Phase 4 Citalopram 20mg;Placebo Oral Tablet
40 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
41 Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery And Postoperative Complications In Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial Recruiting NCT03679611 Phase 4 Sugammadex Sodium;Neostigmine
42 Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis. Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
43 Evaluation of Sperm Selection Technique Using Hyaluronic Acid Binding in Intra-cytoplasmic Sperm Injection (ICSI) Recruiting NCT03999372 Phase 4
44 A Prospective, Double-blind, Randomized, and Controlled Clinical Trial to Compare the Effectiveness of Intravenous Bezlotoxumab (10 mg/kg) Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant Clostridioides Difficile Requiring Surgical Intervention. Recruiting NCT03756454 Phase 4
45 Olanzapine as First Line Treatment for Prevention of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer: a Multicenter, Double-blind and Randomized Trial Recruiting NCT03571126 Phase 4 Olanzapine;Placebos
46 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Recruiting NCT03506750 Phase 4 IVC
47 Randomized Conversion Of Epstein-Barr Virus (EBV)+ Kidney Transplant Recipients Of Living Or Standard Criteria Donors At Three Months Post Transplantation To Belatacept With MPA Or Belatacept With Low-Dose Tacrolimus (50% Of Dose) Compared To Patients Remaining On Center Specific Standard Therapy Of Tacrolimus And MPA Recruiting NCT02213068 Phase 4 belatacept;Tacrolimus;MPA
48 Personalized Indications for Cognitive Behavioural Therapy and Antidepressants in the Treatment of Major Depressive Disorder and Persistent Depressive Disorder Recruiting NCT02752542 Phase 4 Pharmacotherapy
49 Treatment Effect of Colesevelam for Bile Acid Diarrhoea - a Randomised Placebo-controlled Trial Recruiting NCT03876717 Phase 4 Colesevelam Hydrochloride;Placebo oral capsule
50 The Role of Orexin in Human Panic Disorder Active, not recruiting NCT02593682 Phase 4 suvorexant;placebo

Search NIH Clinical Center for Chronic Bilirubin Encephalopathy

Genetic Tests for Chronic Bilirubin Encephalopathy

Anatomical Context for Chronic Bilirubin Encephalopathy

MalaCards organs/tissues related to Chronic Bilirubin Encephalopathy:

40
Breast, Brain, Lung, T Cells, Heart, Thyroid, Liver

Publications for Chronic Bilirubin Encephalopathy

Articles related to Chronic Bilirubin Encephalopathy:

(show all 34)
# Title Authors PMID Year
1
Extreme neonatal hyperbilirubinemia and kernicterus spectrum disorder in Denmark during the years 2000-2015. 61
31907395 2020
2
TcB, FFR, phototherapy and the persistent occurrence of kernicterus spectrum disorder. 61
31911651 2020
3
Management of neonatal jaundice in low- and middle-income countries. 61
31875773 2020
4
Review of bilirubin neurotoxicity I: molecular biology and neuropathology of disease. 61
31600770 2020
5
Bilirubin Induced Encephalopathy. 61
32021624 2020
6
[Clinical characteristics and treatment options of hearing impairment caused by hyperbilirubinemia]. 61
31446717 2019
7
Prebiotics for the prevention of hyperbilirubinaemia in neonates. 61
31425619 2019
8
Hyperbilirubinemia in preterm infants in Japan: New treatment criteria. 61
29906300 2018
9
Extreme neonatal hyperbilirubinemia, acute bilirubin encephalopathy, and kernicterus spectrum disorder in children with galactosemia. 61
29892033 2018
10
Variation in the Phototherapy Practices and Irradiance of Devices in a Major Metropolitan Area. 61
29393277 2018
11
Newborn Bilirubin Screening for Preventing Severe Hyperbilirubinemia and Bilirubin Encephalopathy: A Rapid Review. 61
28071585 2017
12
Facility-based constraints to exchange transfusions for neonatal hyperbilirubinemia in resource-limited settings. 61
27170928 2016
13
A Hypothesis for Using Pathway Genetic Load Analysis for Understanding Complex Outcomes in Bilirubin Encephalopathy. 61
27587993 2016
14
Risk factors for acute bilirubin encephalopathy on admission to two Myanmar national paediatric hospitals. 61
27057339 2015
15
Galactosaemia: an unusual cause of chronic bilirubin encephalopathy. 61
25618877 2015
16
Magnetic resonance imaging of bilirubin encephalopathy: current limitations and future promise. 61
25267277 2014
17
Evaluation and treatment of neonatal hyperbilirubinemia. 61
25077393 2014
18
Outcome analysis of jaundice fast-track system implementation in Thammasat University Hospital. 61
25065088 2014
19
[Crigler-Najjar type 1 in children]. 61
24629116 2013
20
[Crigler-Najjar's syndrome is a rare cause of perinatal hyperbilirubinaemia]. 61
24629117 2013
21
Incidence of chronic bilirubin encephalopathy in Canada, 2007-2008. 61
22966025 2012
22
Relation between serum bilirubin levels ≥450 μmol/L and bilirubin encephalopathy; a Danish population-based study. 61
22176133 2012
23
Birth-related syndromes of athetosis and kernicterus. 61
21496597 2011
24
Screening of infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy: recommendation statement. 61
20704172 2010
25
Putting prevention into practice. Screening of infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. 61
20704173 2010
26
Chronic bilirubin encephalopathy: diagnosis and outcome. 61
20116355 2010
27
Assessing jaundice in infants of 35-week gestation and greater. 61
20463489 2010
28
Systematic review of screening for bilirubin encephalopathy in neonates. 61
19786450 2009
29
Screening of infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy: US Preventive Services Task Force recommendation statement. 61
19786451 2009
30
An emergency medicine approach to neonatal hyperbilirubinemia. 61
17950138 2007
31
[Incidence of kernicterus in newborn infants in Denmark]. 61
16494808 2006
32
Clinical (video) findings and cerebrospinal fluid neurotransmitters in 2 children with severe chronic bilirubin encephalopathy, including a former preterm infant without marked hyperbilirubinemia VIDEO. 61
16264013 2005
33
Neurological complications of kernicterus. 61
16225171 2005
34
Follow-up study of auditory brainstem responses in hyperbilirubinemic newborns treated with exchange transfusion. 61
8992853 1996

Variations for Chronic Bilirubin Encephalopathy

Expression for Chronic Bilirubin Encephalopathy

Search GEO for disease gene expression data for Chronic Bilirubin Encephalopathy.

Pathways for Chronic Bilirubin Encephalopathy

GO Terms for Chronic Bilirubin Encephalopathy

Sources for Chronic Bilirubin Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....